Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

946 ARTÍCULOS , VIENDO DEL 121 AL 135

Amyloid-related Imaging Abnormalities (ARIA) in the Context of Alzheimer's Disease and Amyloid-targeting Therapies: An Introduction for Advanced Practice Providers

Schreiber CP, Kovacik A, Bishop J, Helman J.

Drugs Aging. 2025 Dec;42(12):1103-1111. doi: 10.1007/s40266-025-01253-x. Epub 2025 Oct 3.

TDP-43 in Alzheimer's disease: Pathophysiology and therapeutic strategies

Zhou X, Lin X, He Y, Huang N, Luo Y.

Pharmacol Res. 2025 Nov;221:107977. doi: 10.1016/j.phrs.2025.107977. Epub 2025 Oct 4.

Synaptic scaffold protein PSD-95: a therapeutic target for Alzheimer's disease

Fan X, Wang H, Ping J, Li M, Gu J, Qian W.

Biochem Pharmacol. 2025 Dec;242(Pt 3):117401. doi: 10.1016/j.bcp.2025.117401. Epub 2025 Oct 3.

lncRNA EPB41L4A-AS1: A promising therapeutic target for aging and age-related diseases

Li M, Li T, Zhang X, Li K, Wang Z.

Mech Ageing Dev. 2025 Dec;228:112118. doi: 10.1016/j.mad.2025.112118. Epub 2025 Oct 9.

Beyond amyloid: nanobody-mediated neuroinflammatory therapy for Alzheimer's disease

Amniouel S, Suh J, Zheng W, Zhang Q.

Transl Neurodegener. 2025 Oct 13;14(1):51. doi: 10.1186/s40035-025-00513-5.

Anti-Amyloid Therapies for Alzheimer's Disease: Progress, Pitfalls, and the Path Ahead

Papaliagkas V.

Int J Mol Sci. 2025 Sep 29;26(19):9529. doi: 10.3390/ijms26199529.

[Significance of Amyloid Plaque Removal in Alzheimer's Disease Treatment: Development of Amyloid β-Targeting Antibody Drugs Based on the Amyloid Cascade Hypothesis]

Kowa H, Sato S, Kamiki E, Nishimoto T.

Brain Nerve. 2025 Oct;77(10):1129-1136. doi: 10.11477/mf.188160960770101129.

Small noncoding RNAs: Pioneering a new therapeutic era in Alzheimer's disease

Sahoo S, Pattanaik S, Kar DM, Prusty SK, Sahu PK.

Gene. 2025 Nov 20;972:149827. doi: 10.1016/j.gene.2025.149827. Epub 2025 Oct 15.

Therapeutic potential of 40 Hz flickering light stimulation in Alzheimer's disease: Mechanisms, evidence, and controversies

Wang XY, Jia YJ, Zhang J, Chen JF, Wang YJ, Chen X.

J Alzheimers Dis. 2025 Dec;108(4):1441-1451. doi: 10.1177/13872877251388664. Epub 2025 Oct 22.

Active immunization: A novel therapeutic strategy for treating Alzheimer's disease

Mazahir F.

Eur J Pharmacol. 2025 Nov 15;1007:178288. doi: 10.1016/j.ejphar.2025.178288. Epub 2025 Oct 24.

Alzheimer Combination Therapies: Overview and Scenarios

Cummings JL, Burstein AH, Fillit H.

J Prev Alzheimers Dis. 2025 Dec;12(10):100328. doi: 10.1016/j.tjpad.2025.100328. Epub 2025 Oct 27.

Add-on combination therapy with monoclonal antibodies: Implications for drug development

Cummings J, Burstein AH, Fillit H.

J Prev Alzheimers Dis. 2025 Dec;12(10):100359. doi: 10.1016/j.tjpad.2025.100359. Epub 2025 Oct 27.

Peripheral immune and metabolic regulation of Aβ and Tau by exercise in Alzheimer's disease

Yu Y, Chen K.

Front Immunol. 2025 Oct 15;16:1678526. doi: 10.3389/fimmu.2025.1678526. eCollection 2025.

Tau Liquid-Liquid Phase Separation in Alzheimer's Disease: Mechanisms, Pathogenesis, and Therapeutic Implications

Tian S, Liu Y, Hu H, Li S.

Mol Neurobiol. 2025 Nov 9;63(1):18. doi: 10.1007/s12035-025-05280-y.

APOE-Targeted Therapeutics for Alzheimer's Disease

Yassine HN, Hugo C, O'Donovan B, Stephens IO, Johnson LA, Cole G, Tcw J, Johansson J, Kisler K, Chiba-Falek O.

J Neurosci. 2025 Nov 12;45(46):e1388252025. doi: 10.1523/JNEUROSCI.1388-25.2025.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias